Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10682082 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MMP2ANPEPMAPTBRD4 | |
| SCHEMBL10933454 | 0.79 | MAPT (0.32) | MAPT | |
| SCHEMBL7527506 | 0.73 | — | — | |
| SCHEMBL1804088 | 0.68 | — | — | |
| SCHEMBL18539526 | 0.68 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL2897989 | 0.68 | MCL1 (0.51) | ALDH1A1MAPT | |
| SCHEMBL2597463 | 0.66 | BRD4 (0.45) | ALDH1A1MMP2ANPEPBRD4CYP1A2 | |
| SCHEMBL6249198 | 0.65 | MAPK1 (0.49) | ALDH1A1MAPK1CYP1A2KMT2A | |
| SCHEMBL6249194 | 0.65 | MAPK1 (0.49) | ALDH1A1MAPK1CYP1A2KMT2A | |
| SCHEMBL8004969 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003002058-A9 | BONE ANABOLIC COMPOUNDS AND METHODS OF USE | ANABONIX INC (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-1404344-A2 | BONE ANABOLIC COMPOUNDS AND METHODS OF USE | Anabonix, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030119800-A1 | Bone anabolic compounds and methods of use | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2003-06-26 | — | — | US | disclosed |
| WO-2003002058-A2 | BONE ANABOLIC COMPOUNDS AND METHODS OF USE | ANABONIX, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119800-A1 | Bone anabolic compounds and methods of use | SHBG, BMP2, BMP4 | ALDH1A1 1965/4885MMP2 925/4885ANPEP 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.